{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:24:10Z","timestamp":1793651050539,"version":"4.5.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-023-02586-9","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T06:22:54Z","timestamp":1687587774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Core Shell Lipid-Polymer Hybrid Nanoparticles for Oral Bioavailability Enhancement of Ibrutinib via Lymphatic Uptake"],"prefix":"10.1208","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4544-6877","authenticated-orcid":false,"given":"Mitali","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrushti","family":"Kansara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"issue":"19","key":"2586_CR1","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.3390\/molecules25194377","volume":"25","author":"A Mohanty","year":"2020","unstructured":"Mohanty A, Uthaman S, Park IK. Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy. Molecules. 2020;25(19):4377. https:\/\/doi.org\/10.3390\/molecules25194377.","journal-title":"Molecules."},{"key":"2586_CR2","doi-asserted-by":"publisher","first-page":"119794","DOI":"10.1016\/j.ijpharm.2020.119794","volume":"588","author":"H Elkateb","year":"2020","unstructured":"Elkateb H, Tatham LM, Cauldbeck H, Niezabitowska E, Owen A, Rannard S, McDonald T. Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. Int J Pharm. 2020;588:119794. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119794.","journal-title":"Int J Pharm."},{"issue":"12","key":"2586_CR3","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2147\/DDDT.S172199","volume":"25","author":"J Liu","year":"2018","unstructured":"Liu J, Cheng H, Han L, Qiang Z, Zhang X, Gao W, Zhao K, Song Y. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2018;25(12):3199\u2013209. https:\/\/doi.org\/10.2147\/DDDT.S172199.","journal-title":"Drug Des Devel Ther."},{"issue":"1","key":"2586_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1208\/s12249-022-02479-3","volume":"24","author":"P Dali","year":"2023","unstructured":"Dali P, Shende P. Self-assembled lipid polymer hybrid nanoparticles using combinational drugs for migraine via intranasal route. AAPS PharmSciTech. 2023;24(1):20. https:\/\/doi.org\/10.1208\/s12249-022-02479-3.","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"2586_CR5","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lu Y, Qi J, Wu W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B. 2021;11(8):2449\u201368. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.022.","journal-title":"Acta Pharm Sin B."},{"issue":"5","key":"2586_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s0928-0987(02)00051-9","volume":"15","author":"CM O\u2019Driscoll","year":"2002","unstructured":"O\u2019Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15(5):405\u201315. https:\/\/doi.org\/10.1016\/s0928-0987(02)00051-9.","journal-title":"Eur J Pharm Sci."},{"key":"2586_CR7","doi-asserted-by":"publisher","unstructured":"Ismail AI. Experimental and density functional theory characteristics of ibrutinib, a Bruton\u2019s kinase inhibitor approved for leukemia treatment. J \nSpectrosc. 2021;1-8. https:\/\/doi.org\/10.1155\/2021\/9968797.","DOI":"10.1155\/2021\/9968797"},{"issue":"7","key":"2586_CR8","first-page":"483","volume":"39","author":"S Parmar","year":"2014","unstructured":"Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014;39(7):483\u2013519.","journal-title":"P T."},{"issue":"6","key":"2586_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/1573412915666190314124932","volume":"15","author":"AS Alshetaili","year":"2019","unstructured":"Alshetaili AS, Ansari MJ, Anwer MK, Ganaie MA, Iqbal M, Alshahrani SM, Alalaiwe AS, Alsulays BB, Alshehri S, Sultan AS. Enhanced oral bioavailability of ibrutinib encapsulated poly (lactic-co- glycolic acid) nanoparticles: pharmacokinetic evaluation in rats. Curr Pharm Analysis. 2019;15(6):661\u20138. https:\/\/doi.org\/10.2174\/1573412915666190314124932.","journal-title":"Curr Pharm Analysis."},{"issue":"6","key":"2586_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/jphp.12550","volume":"68","author":"F Shakeel","year":"2016","unstructured":"Shakeel F, Iqbal M, Ezzeldin E. Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. J Pharm Pharmacol. 2016;68(6):772\u201380. https:\/\/doi.org\/10.1111\/jphp.12550.","journal-title":"J Pharm Pharmacol."},{"issue":"8","key":"2586_CR11","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1208\/s12249-018-1147-4","volume":"19","author":"Q Qiu","year":"2018","unstructured":"Qiu Q, Lu M, Li C, Luo X, Liu X, Hu L, et al. Novel self-assembled ibrutinib-phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility. AAPS PharmSciTech. 2018;19(8):3571\u201383. https:\/\/doi.org\/10.1208\/s12249-018-1147-4.","journal-title":"AAPS PharmSciTech."},{"issue":"20","key":"2586_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1524-7","volume":"2019","author":"N Rangaraj","year":"2019","unstructured":"Rangaraj N, Pailla SR, Chowta P, Sampathi S. Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability. AAPS PharmSciTech. 2019;2019(20):1\u201318. https:\/\/doi.org\/10.1208\/s12249-019-1524-7.","journal-title":"AAPS PharmSciTech"},{"key":"2586_CR13","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1016\/j.xphs.2019.04.031","volume":"108","author":"X Shi","year":"2019","unstructured":"Shi X, Song S, Ding Z, Fan B, Huang W, Xu T. Improving the solubility, dissolution, and bioavailability of ibrutinib by preparing it in a Coamorphous state with saccharin. J Pharm Sci. 2019;108:3020\u20138. https:\/\/doi.org\/10.1016\/j.xphs.2019.04.031.","journal-title":"J Pharm Sci."},{"issue":"5","key":"2586_CR14","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s13346-020-00803-7","volume":"10","author":"N Rangaraj","year":"2020","unstructured":"Rangaraj N, Pailla SR, Shah S, Prajapati S, Sampathi S. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Deliv Transl Res. 2020;10(5):1476\u201394. https:\/\/doi.org\/10.1007\/s13346-020-00803-7.","journal-title":"Drug Deliv Transl Res."},{"issue":"9","key":"2586_CR15","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1021\/mp300202c","volume":"9","author":"S Jain","year":"2012","unstructured":"Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharm. 2012;9(9):2626\u201335. https:\/\/doi.org\/10.1021\/mp300202c.","journal-title":"Mol Pharm."},{"key":"2586_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1208\/s12249-010-9410-3","volume":"11","author":"L Hu","year":"2010","unstructured":"Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2010;11:582\u20137. https:\/\/doi.org\/10.1208\/s12249-010-9410-3.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"2586_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3892\/or.2018.6492","volume":"40","author":"Y Yuan","year":"2018","unstructured":"Yuan Y, Chiba P, Cai T, Callaghan R, Bai L, Cole SPC, Cai Y. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells. Oncol Rep. 2018;40(2):1055\u201363. https:\/\/doi.org\/10.3892\/or.2018.6492.","journal-title":"Oncol Rep."},{"key":"2586_CR18","doi-asserted-by":"publisher","first-page":"105715","DOI":"10.1016\/j.ejps.2021.105715","volume":"159","author":"P Patel","year":"2021","unstructured":"Patel P, Patel M. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation. Eur J Pharm Sci. 2021;159:105715. https:\/\/doi.org\/10.1016\/j.ejps.2021.105715.","journal-title":"Eur J Pharm Sci."},{"issue":"2","key":"2586_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbrc.2019.09.004","volume":"519","author":"C Zeng","year":"2019","unstructured":"Zeng C, Zheng R, Yang X, Du Y, Xing J, Lan W. Improved oral delivery of tilianin through lipid-polymer hybrid nanoparticles to enhance bioavailability. Biochem Biophys Res Commun. 2019;519(2):316\u201322. https:\/\/doi.org\/10.1016\/j.bbrc.2019.09.004.","journal-title":"Biochem Biophys Res Commun."},{"issue":"31","key":"2586_CR20","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1039\/d1tb00806d","volume":"9","author":"X Bao","year":"2021","unstructured":"Bao X, Qian K, Yao P. Insulin- and cholic acid-loaded zein\/casein-dextran nanoparticles enhance the oral absorption and hypoglycemic effect of insulin. J Mater Chem B. 2021;9(31):6234\u201345. https:\/\/doi.org\/10.1039\/d1tb00806d.","journal-title":"J Mater Chem B."},{"issue":"22","key":"2586_CR21","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/la103576a","volume":"26","author":"RH Fang","year":"2010","unstructured":"Fang RH, Aryal S, Hu CM, Zhang L. Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir. 2010;26(22):16958\u2013169562. https:\/\/doi.org\/10.1021\/la103576a.","journal-title":"Langmuir."},{"issue":"1","key":"2586_CR22","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1038\/s41598-017-06142-x","volume":"7","author":"Q Wang","year":"2017","unstructured":"Wang Q, Alshaker H, B\u00f6hler T, Srivats S, Chao Y, Cooper C, Pchejetski D. Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. Sci Rep. 2017;7(1):5901. https:\/\/doi.org\/10.1038\/s41598-017-06142-x.","journal-title":"Sci Rep."},{"key":"2586_CR23","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/IJN.S41521","volume":"8","author":"A Khan","year":"2013","unstructured":"Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733\u201344. https:\/\/doi.org\/10.2147\/IJN.S41521.","journal-title":"Int J Nanomedicine."},{"issue":"9","key":"2586_CR24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/nano9091185","volume":"9","author":"R Mare","year":"2019","unstructured":"Mare R, Da H, Fresta M, Cosco D, Awasthi V. Anchoring property of a novel hydrophilic lipopolymer, HDAS-SHP, post-inserted in preformed liposomes. Nanomaterials (Basel). 2019;9(9):1185. https:\/\/doi.org\/10.3390\/nano9091185.","journal-title":"Nanomaterials (Basel)."},{"issue":"1","key":"2586_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","volume":"532","author":"J Leal","year":"2017","unstructured":"Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int J Pharm. 2017;532(1):555\u201372. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.09.018.","journal-title":"Int J Pharm."},{"key":"2586_CR26","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.2147\/IJN.S209325","volume":"14","author":"N Tahir","year":"2019","unstructured":"Tahir N, Madni A, Correia A, Rehman M, Balasubramanian V, Khan MM, Santos HA. Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy. Int J Nanomed. 2019;14:4961\u201374. https:\/\/doi.org\/10.2147\/IJN.S209325.","journal-title":"Int. J. Nanomed."},{"key":"2586_CR27","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2147\/ijn.s45231","volume":"8","author":"MS Freag","year":"2013","unstructured":"Freag MS, Elnaggar YS, Abdallah OY. Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomed. 2013;8:2385\u201397. https:\/\/doi.org\/10.2147\/ijn.s45231.","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"2586_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/10717544.2017.1321062","volume":"24","author":"F Yu","year":"2017","unstructured":"Yu F, Ao M, Zheng X, Li N, Xia J, Li Y, Li D, Hou Z, Qi Z, Chen XD. PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency. Drug Deliv. 2017;24(1):825\u201333. https:\/\/doi.org\/10.1080\/10717544.2017.1321062.","journal-title":"Drug Deliv."},{"issue":"6","key":"2586_CR29","doi-asserted-by":"publisher","first-page":"025403","DOI":"10.1088\/2053-1591\/aaed72","volume":"2018","author":"L Le","year":"2018","unstructured":"Le L, Bokare A, Erogbogbo F. Hand powered, cost effective, 3D printed nanoparticle synthesizer: effects of polymer end caps, drugs, and solvents on lipid polymer hybrid nanoparticles. Mater Res Express. 2018;2018(6):025403\u201312. https:\/\/doi.org\/10.1088\/2053-1591\/aaed72.","journal-title":"Mater Res Express."},{"issue":"15","key":"2586_CR30","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2217\/nnm-2017-0011","volume":"12","author":"A Jain","year":"2017","unstructured":"Jain A, Sharma G, Kushwah V, Garg NK, Kesharwani P, Ghoshal G, Singh B, Shivhare US, Jain S, Katare OP. Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer. Nanomedicine. 2017;12(15):1851\u201372. https:\/\/doi.org\/10.2217\/nnm-2017-0011.","journal-title":"Nanomedicine."},{"issue":"6","key":"2586_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/pharmaceutics11060272","volume":"11","author":"A Tunsirikongkon","year":"2019","unstructured":"Tunsirikongkon A, Pyo YC, Kim DH, Lee SE, Park JS. Optimization of polyarginine-conjugated PEG lipid grafted proliposome formulation for enhanced cellular association of a protein drug. Pharmaceutics. 2019;11(6):272. https:\/\/doi.org\/10.3390\/pharmaceutics11060272.","journal-title":"Pharmaceutics."},{"key":"2586_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jddst.2019.03.039","volume":"51","author":"RS Jadon","year":"2019","unstructured":"Jadon RS, Sharma M. Docetaxel-loaded lipid-polymer hybrid nanoparticles for breast cancer therapeutics. J Drug Deliv Sci Tech. 2019;51:475\u201384. https:\/\/doi.org\/10.1016\/j.jddst.2019.03.039.","journal-title":"J Drug Deliv Sci Tech."},{"key":"2586_CR33","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1039\/C6NJ02819E","volume":"41","author":"SQ Zeng","year":"2017","unstructured":"Zeng SQ, Chen YZ, Chen Y, Liu H. Lipid-polymer hybrid nanoparticles for synergistic drug delivery to overcome cancer drug resistance. New J Chem. 2017;41:1518\u201325. https:\/\/doi.org\/10.1039\/C6NJ02819E.","journal-title":"New J Chem."},{"issue":"1","key":"2586_CR34","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ijpharm.2017.09.040","volume":"532","author":"SS Bachhav","year":"2017","unstructured":"Bachhav SS, Dighe VD, Devarajan PV. Rifampicin lipid-polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer\u2019s patch uptake. Int J Pharm. 2017;532(1):612\u201322. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.09.040.","journal-title":"Int J Pharm"},{"issue":"8","key":"2586_CR35","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/pharmaceutics13081261","volume":"13","author":"RX Zhang","year":"2021","unstructured":"Zhang RX, Dong K, Wang Z, Miao R, Lu W, Wu XY. Nanoparticulate drug delivery strategies to address intestinal cytochrome P450 CYP3A4 metabolism towards personalized medicine. Pharmaceutics. 2021;13(8):1261. https:\/\/doi.org\/10.3390\/pharmaceutics13081261.","journal-title":"Pharmaceutics."},{"issue":"1","key":"2586_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/17425247.1.1.141","volume":"1","author":"M Shakweh","year":"2004","unstructured":"Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer\u2019s patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv. 2004;1(1):141\u201363. https:\/\/doi.org\/10.1517\/17425247.1.1.141.","journal-title":"Expert Opin Drug Deliv."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02586-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-023-02586-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-023-02586-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:07:35Z","timestamp":1692709655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-023-02586-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1208\/s12249-023-02586-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"142"}}